6.1.3. non-seminomatous germ cell tumours clinical stage i. management options cs nsgcts include surveillance adjuvant chemotherapy. retroperitoneal lymph node dissection limited role. overall, approximately 70% cs nsgcts cured orchiectomy alone. high-risk feature lvi, historical figures reported relapse 50% compared 15% without lvi. thorough discussion undertaken patient outlining potential advantages disadvantages treatment options, well individual co-morbidities, disease features, risk factors, specific circumstances, personal preferences, guide treatment decision. 6.1.3.1. surveillance surveillance cs nsgct entails strict protocol repeated cross-sectional imaging, monitoring serum tumour markers clinical assessment early identification patients experiencing relapse must receive salvage treatment (see table 11). largest reports surveillance indicate cumulative relapse risk 30% cs nsgct (five-year conditional risk relapse 42% 17% high- low-risk cs i-nsgct, respectively) . these, 92% present within first two years [101,103,116-118]. 6.1.3.2. retroperitoneal lymph node dissection since introduction cisplatin-based chemotherapy role adjuvant primary retroperitoneal lymph node dissection (rplnd) men cs nsgcts decreased. according data high-volume expert centres, primary rplnd associated risk relapse < 15% . recent data report relapse rate 10% case negative nodes (pathologic stage (ps) – i) < 30% case nodal metastases (ps ii) [119-121], possibly due selection stage migration. indications cs disease include men teratoma somatic malignant component, patients willing suitable undergo chemotherapy case recurrence, particular vascular invasion present. recent publication supports safety surveillance alone, ps ii disease following rplnd, 75-80% relapse free two five years [120-122]. relapse rescued standard chemotherapy . ps ii, adjuvant chemotherapy comprising two cycles (b)ep (except cases ppt (post pubertal teratoma) only) standard option discussed individual. strategies reduce morbidity primary rplnd include nerve-sparing minimally invasive approaches. multi-centre setting, higher rates in-field recurrences complications reported nerve-sparing rplnd . suggests primary rplnd, indicated chosen, performed experienced surgeon specialist centre. minimally invasive (laparoscopic robot-assisted) primary rplnd, appears feasible safe (e.g., low-complication rate) experienced hands. must performed high-volume rplnd centres appropriate minimal-invasive surgery expertise [127-134]. limited recent data mid-term follow-up. despite advantages, including good efficacy, less-demanding costly follow-up due reduced need cross-sectional imaging , rplnd cs nsgct diminished role view high css rates surveillance, low relapse rates adjuvant chemotherapy, lower reproducibility primary rplnd large scale. 6.1.3.3. adjuvant chemotherapy adjuvant chemotherapy evaluated one two cycles bep (cisplatin, etoposide, bleomycin) cs nsgct. prospective trial 1996, well subsequent studies, used two cycles bep high-risk patients (lvi present) [136-138]. series, including 200 patients, median follow-up nearly 7.9 years , relapse rate 2.7% reported, minimal long-term toxicity. two cycles cisplatin-based adjuvant chemotherapy appear adversely affect fertility sexual activity . studies shown one cycle adjuvant bep results similar low recurrence rates (2-3%) . reduction two one cycle bep improves risk-benefit ratio adjuvant chemotherapy considerably. randomised phase iii trial also compared two-year recurrence free survival adjuvant bep x 1 rplnd. results favoured chemotherapy recurrence free survival 99.5% vs. 91% . clinically relevant differences quality life (qol) detected . community based prospective study 490 unselected patients cs nsgct received adjuvant single cycle bep five-year relapse rates 3% 2% lvi+ lv- patients, respectively. median follow-up eight years rates sustained, relapses observed beyond 3.3 years . numbers imply > 90% relapses prevented single cycle bep recommended strategy adjuvant chemotherapy considered . very-long term (> 20 years) side effects adjuvant chemotherapy, particularly cardiovascular, yet fully defined considered shared decision-making . limited data available outcomes relapse adjuvant bep. retrospective analysis indicated one third relapses late outcome may slightly worse compared presenting de novo metastatic disease . 6.1.3.4. risk-adapted treatment risk-adapted strategy alternative single approach patients cs nsgct. advantages disadvantages treatment options must discussed patients context specific circumstances including disease risk factors, co-morbidities, personal preference, well clinician recommendation reaching treatment decision. lympho-vascular invasion strongest reproducible predictive factor relapse carefully outlined patient assist decision-making. patients without lvi guided consider surveillance, although patients significant co-morbidities concerns regarding salvage chemotherapy multicycle cisplatin-based chemotherapy may opt adjuvant therapy. lvi high risk relapse (up 50%) highlighted guided consider adjuvant management, chemotherapy bep x 1 “preferred” option. patients may wish consider primary rplnd although need aware potential additional requirement adjuvant chemotherapy nodes contain active disease (pn1), well 10% risk systemic relapse, even pn0, requiring subsequent chemotherapy treatment (bep x 3). 6.1.3.5. post-pubertal teratoma somatic malignant component multi-institutional study analysing retrospective datasets cs patients post-pubertal teratoma somatic malignant component (tsmc) suggested patients inferior five-year os approximately 10% compared cs gct patients. furthermore, cs tsmc cases undergoing primary rpplnd much higher proportion nodal metastases (ps ii) expected (37.5%). despite limitations, study provides evidence issue supports primary rplnd cs nsgct tsmc . patients presenting cs pure post-pubertal teratoma without somatic malignant component, surveillance provides comparable survival outcomes primary rplnd . mixed population based study 237 cs pure teratoma testis, showed increasing trend favouring surveillance rplnd well significant difference overall survival median follow-up 54 months . however, subtype discrepancies primary diagnostic post-pubertal teratoma infrequent consist addition subtype involve secondary somatic type malignancy 83% cases. such, central review expert genitourinary pathologist recommended teratoma diagnosed orchidectomy specimen . 6.1.3.6. summary evidence recommendations treatment clinical stage non-seminoma germ cell tumour testis summary evidencelelymphovascular invasion increases risk relapse.2athe relapse rate active surveillance 50%, lvi present.2athe relapse rate patients receive adjuvant chemotherapy bep (x 1 cycle) 3%.2aadjuvant chemotherapy bep x 1 superior adjuvant rplnd terms risk relapse 2 strategies centralised expert centres.1ba risk-adapted approach, based lvi invasion feasible.2bthe acute toxicity one cycle adjuvant bep low.1b recommendationsstrength ratinginform patients management options orchidectomy: surveillance, adjuvant chemotherapy, retroperitoneal lymph node dissection, including treatment-specific recurrence rates well acute long-term side effects.strongoffer surveillance risk-adapted treatment based lymphovascular invasion (see below).strongdiscuss one course cisplatin, etoposide, bleomycin adjuvant treatment alternative patients stage non-seminomatous germ cell tumour patients willing undergo comply surveillance.strong 6.1.3.7. recommendations risk-adapted treatment clinical stage non-seminomatous germ cell tumour based vascular invasion recommendationsstrength ratingstage ia (pt1, vascular invasion): low riskoffer surveillance patient willing able comply.strongoffer adjuvant chemotherapy one course cisplatin, etoposide, bleomycin (bep) low-risk patients willing (or unsuitable) undergo surveillance.strongstage ib (pt2-pt4): high riskoffer adjuvant chemotherapy one course bep, surveillance discuss advantages disadvantages.strongoffer surveillance patients willing undergo adjuvant chemotherapy.strongoffer nerve-sparing retroperitoneal lymph node dissection highly selected patients only; contraindication adjuvant chemotherapy unwilling accept surveillance.strong figure 1: risk-adapted treatment patients clinical stage non-seminoma nsgct* * discuss treatment options individual patients, allow make informed decision care.** case ps ii, rate recurrence higher chemotherapy administered (max. 2 cycles).bep = cisplatin, etoposide, bleomycin; cs = clinical stage; igcccg = international germ cell cancer collaborative group; ns = nerve-sparing; rlnpd = retroperitoneal lymph node dissection; vip = etoposide, cisplatin, ifosfamide.